Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model |
| |
Authors: | Pierre Bessiè re,Marine Wasniewski,Evelyne Picard-Meyer,Alexandre Servat,Thomas Figueroa,Charlotte Foret-Lucas,Amelia Coggon,Sandrine Lesellier,Frank Boué ,Nathan Cebron,Blandine Gausserè s,Catherine Trumel,Gilles Foucras,Francisco J. Salguero,Elodie Monchatre-Leroy,Romain Volmer |
| |
Abstract: | Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one day pre-infection or one day post-infection limited weight loss and decreased viral lung titers. By contrast, intranasal administration of IFN-α starting at the onset of symptoms three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our results provide evidence that early type I IFN treatment is beneficial, while late interventions are ineffective, although not associated with signs of enhanced disease. |
| |
Keywords: | |
|
|